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Upregulation of fatty acid synthase (FASN) is a common event in cancer, although its
mechanistic and potential therapeutic roles are not completely understood. In this study, we
establish a key role of FASN during transformation. FASN is required for eliciting the ana-
plerotic shift of the Krebs cycle observed in cancer cells. However, its main role is to consume
acetyl-CoA, which unlocks isocitrate dehydrogenase (IDH)-dependent reductive carboxyla-
tion, producing the reductive power necessary to quench reactive oxygen species (ROS)
originated during the switch from two-dimensional (2D) to three-dimensional (3D) growth
(a necessary hallmark of cancer). Upregulation of FASN elicits the 2D-to-3D switch; however,
FASN's synthetic product palmitate is dispensable for this process since cells satisfy their
fatty acid requirements from the media. In vivo, genetic deletion or pharmacologic inhibition
of FASN before oncogenic activation prevents tumor development and invasive growth.
These results render FASN as a potential target for cancer prevention studies.
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Fatty acid synthase (FASN) is a multienzyme protein thatcatalyzes the synthesis of fatty acids (mainly the long-chainsaturated fatty acid palmitate) from acetyl-CoA and
malonyl-CoA in the presence of nicotinamide adenine dinu-
cleotide phosphate reduced form (NADPH)1. Most adult tissues
satisfy their fatty acid needs by uptaking circulating fatty acids
from the bloodstream1,2. A constant fatty acid supply to the
bloodstream is generated by nutrition and lipid storage in adi-
pocytes and hepatocytes2. A common feature of tumors from
different lineages is FASN overexpression3–9. A transgenic mouse
model that overexpresses FASN in prostate tissue showed tumor-
promoting properties of this enzyme10. Constitutive FASN
knockout is lethal in the early embryonic stages11. Regarding the
adult animal, several studies by Semenkovich and colleagues12–17
demonstrated the involvement of FASN in several physiologic
processes. However, conditional deletion is only lethal in the case
of the gastrointestinal tract18. Taken together, these findings
indicate a potential oncogenic role of FASN and a potential high
therapeutic index due to the lack of essentiality in most normal
tissues.
The effects of FASN inhibition in developed tumors have been
well studied. Early inhibitors such as cerulenin, C75, or orlistat
only showed modest antitumor effects8,19–25. Similar efficacy was
observed with second-generation, non-clinical-grade FASN
inhibitors26,27 or gene-silencing approaches24,28,29. Although
mature data from the first clinical-grade inhibitor are not avail-
able, preliminary results do not indicate that targeting FASN may
eradicate established tumors30.
Conversely, the role of FASN could be different during the
carcinogenesis process. Complex metabolic rearrangements occur
during the transition from normal to malignant cells31. Such
events require tight regulation, and changes in FASN activity
might cause interferences due to the following reasons: (1) FASN
activity accounts for the highest cell consumption of NADPH1, a
key regulator of the REDOX balance, which is altered but highly
regulated in cancer cells32; (2) the ability to grow in three
dimensions (3D) in the absence of intercellular matrix attachment
is a necessary hallmark that transforming cells must acquire to
develop clinical tumors33, and requires quenching an excess of
reactive-oxygen species (ROS)34; 3) FASN also consumes acetyl-
CoA, which in turn regulates the entrance of glycolysis-derived
pyruvate in the Krebs cycle35. The anaplerotic shift of the Krebs
cycle is also one key characteristic of cancer-rewired metabo-
lism31. Since tumor cells can satisfy their fatty acid needs by
active uptake from the bloodstream36, we hypothesized that
FASN activity could be essential during the initial steps of the
transformation process and thus be a target for cancer prevention.
Although in established tumors FASN upregulation has been
described as a “cancer autonomous” system to generate its own
lipid pools1,37,38, in the proposed model the requirement of FASN
by transforming cells would be unrelated to the enzymatic
product.
To study the role of FASN and its involvement in the metabolic
reprogramming events that occur during transformation, we
designed several in vitro and in vivo models to temporally and
spatially control FASN expression. Across models driven by
diverse oncogenic hits such as HER2, KRAS, or PyMT (poly-
omarivurs middle T antigen), we showed how FASN is essential
for sustaining the isocitrate dehydrogenase 1 (IDH1)-dependent
reductive carboxylation of glutamine39,40 that allows quenching
excessive ROS produced during the transition from two-
dimensional (2D) growth to 3D anchorage-independent growth,
a hallmark of cancer33. The presence of FASN synthetic product
in the system does not modify this essentiality. The in vivo
implications of these effects in different mouse models were
prevention of tumorigenesis.
Results
FASN is essential during the transformation process. We
developed a FASN conditional allele where exons 4–8 were
flanked by loxP sites (FASNlox). We used this allele in combi-
nation with a 4-hydroxytamoxifen-inducible Cre recombinase
under the control of the ubiquitin C promoter (UBC-CreERT2)41
(Supplementary Fig. 1a). We isolated and immortalized mouse
embryonic fibroblasts (MEFs) from FASNlox/lox mice. FASNlox/lox
MEFs were infected with retroviral particles expressing the
PyMT breast cancer oncogene, KRAS (G12D), or HER2
(A775_G776insYVMA)42 (FASNlox/lox-PyMT, FASNlox/lox-
KRAS, and FASNlox/lox-HER2, respectively; Supplementary
Fig. 1b). Colony formation assay showed that the three oncogenes
transformed FASNlox/lox MEFs (Fig. 1a and Supplementary
Fig. 1c), but only in the presence of palmitate (Supplementary
Fig. 4f). When FASNlox/lox MEFs were infected with adenoviral
particles expressing Cre to eliminate the conditional FASN allele
prior to PyMT, KRAS (G12D), or HER2 (A775_G776insYVMA)
expression (FASNΔ/Δ-PyMT, FASNΔ/Δ-KRAS, and FASNΔ/Δ-
HER2, respectively), virtually no colonies were recovered (Fig. 1a
and Supplementary Fig. 1c). The same inability to form colo-
nies was observed when wild-type, immortalized murine breast
epithelial cells HC11 were compared with clustered regularly
interspaced short palindromic repeat (CRISPR)-deleted FASN
variants transfected with PyMT, KRAS (G12D), or HER2 (Sup-
plementary Fig. 1e–g). Interestingly, the few colonies recovered
from the FASNΔ/Δ-PyMT soft agar culture preserved important
residual FASN messenger RNA (mRNA) and protein levels
(Fig. 1b), indicating the colony formation process occurred only
in “escapers” (i.e., due to the <100% efficient adenovirus-
expressing Cre-recombinase (adeno-Cre) infection process).
Despite the different ability to form colonies in soft agar, pro-
liferation and apoptotic rates were unaffected by FASN depletion
in 2D cultures (Fig. 1c, d, d). Although FASNΔ/Δ clones were
unable to form colonies, it is important to mention that minor
FASN-level fluctuations observed among different FASNlox/lox-
PyMT clones were not related to an impaired or improved clo-
nogenic ability (Supplementary Fig. 2a, d); similar observations
applied for FASNlox/lox-KRAS and FASNlox/lox-HER2 (Supple-
mentary Fig. 2b, c, e, f). Finally, although non-statistically sig-
nificant, the lower replication rate of FASNΔ/Δ clones in 2D
cultures could account for a decreased integration of retroviral
particles containing the studied oncogenes, but the examination
of PyMT, KRAS, and HER2 levels across different FASNΔ/Δ and
FASNlox/lox clones did not reveal significant differences (Sup-
plementary Fig. 2g).
FASN loss impairs metabolic changes during transformation.
Phosphoinositide-3-kinase-protein kinase B/Akt (PI3K-AKT)
and mitogen-activated protein kinase (MAPK) hyperactivation
are the most frequent oncogenic alterations found in human
tumors regardless of the lineage of origin43. PyMT-transformed
cells show hyperactive PI3K-AKT and MAPK pathways and a
strong Warburg effect44–48. KRAS mutations and HER2 signaling
are also associated with similar metabolic traits47,49. We hypo-
thesized that the lack of FASN would impair glycolysis and the
anaplerotic shift of the Krebs cycle31 based on the scheme shown
in Fig. 2a.
Congruently with the lack of FASN, we observed an increase in
acetyl-CoA and NADPH in FASNΔ/Δ-PyMT compared with
FASNlox/lox-PyMT MEFs (Fig. 2b), which was coupled to a >6-
fold decrease in pyruvate dehydrogenase activity (Supplementary
Fig. 3a). By using an in vitro assay with mitochondrial lysates (i.e.,
in conditions where the original mitochondrial stoichiometry is
lost), we observed a trend to phenocopy such inhibition by
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adding acetyl-CoA to FASNlox/lox-PyMT lysates: pyruvate
dehydrogenase activity was similar to that of FASNΔ/Δ-PyMT
MEFS, but not statistically significantly different—albeit lower—
to that of FASNlox/lox-PyMT MEFS (Supplementary Fig. 3a).
FASNlox/lox-PyMT MEFs showed the maximum glycolytic
(reflected in extracellular acidification rate, ECAR) (Fig. 2c) and
oxygen consumption rate (OCR) (Fig. 2d), matching other
metabolic observations in transformed cells31,50. In the absence of
the PyMT oncogene, both MEFs with and without FASN
(FASNlox/lox-Empty and FASNΔ/Δ-Empty, respectively) showed
similar ECAR and OCR. However, we observed a very low
respiration (baseline and maximal respiratory capacity) and
glycolytic capacity (similar to the non-transformed MEFs; Fig. 2c)
when FASN was deleted prior to attempting transformation with
PyMT (FASNΔ/Δ-PyMT). The pre-transformation absence of
FASN led to the same metabolic phenotype in HC-11 cells
transformed with PyMT or KRAS (HC11-FASNKO-PyMT and
HC11-FASNKO-KRAS, respectively) (Supplementary Fig. 3b) and
in MEFs transformed with HER2 or KRAS (FASNΔ/Δ-HER2 and
FASNΔ/Δ-KRAS, respectively) (Supplementary Fig. 3c). The lack
of FASN also led to an inversion of the NAD+/NADH quotient,
indicating a decreased capacity of NAD+ regeneration (Supple-
mentary Fig. 3d).
Mitochondrial polarization is initiated by the generation of
NADH/FADH during carbon skeleton flux along the Krebs cycle.
ROS originate from electron dissipation that occurs when ATP is
synthesized coupled to O2 reduction by ATP synthase. The lack
of negative mitochondrial charging (Fig. 2e) and the lack of ROS
production in the FASNΔ/Δ-PyMT MEFs (Fig. 2f) indicate that
the mitochondrial membrane is not polarized in the absence of
FASN, explaining the low OCR observed.
Next, we performed carbon-tracing experiments with [U-13C6]
glucose (Fig. 3a). Several findings are noteworthy: first, the levels
of unlabeled lipids were similar in FASNlox/lox-PyMT and
FASNΔ/Δ-PyMT MEFs; however, labeled lipid pools were
virtually absent in the latter (Fig. 3b). This fact suggests the
relative independence from FASN activity to maintain stable
intracellular lipids levels and indicates that the abrogation of
transformation is not dependent of FASN enzymatic product.
Second, the comparative levels of certain glycolysis intermediate
isotopomers (lactate CH3 ions) and isotopologs [glucose-6-P
(m+ 6) and fructose-6-P (m+ 6)] showed a >2-fold decrease in
the glycolytic rate in FASNΔ/Δ-PyMT MEFs compared with
FASNlox/lox-PyMT (Fig. 3c), regardless of the compensatory
upregulation of Glut1 (trend) and Glut4 (statistically significant)
in FASNΔ/Δ-PyMT MEFs (Fig. 3d). Third, the rate of incorpora-
tion of carbon skeletons derived from glucose into the Krebs cycle
(evidenced by the levels of the m+ 2 isotopologs of citrate,
aconitate, fumarate, and malate, and –CH2 succinate isotopomer)
was also diminished in FASNΔ/Δ-PyMT MEFs compared with
FASNlox/lox-PyMT (Fig. 3e, f). Fourth, we observed a diminished
incorporation of glucose-derived carbons of the m+ 5 isotopoloe,
corresponding to the ribose moiety of ADP ribose and AMP, in
FASNΔ/Δ-PyMT MEFs indicating a decrease in the pentose
phosphate pathway flow (Fig. 3g). Taken together, these data
confirm that when transformation is initiated in the absence of
FASN, an accumulation of FASN substrates linked to a failure in
the upregulation of glycolysis and the Krebs cycle is observed.
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Fig. 1 FASN is essential for PyMT-dependent transformation in vitro. a Representative images of the soft agar colony assay and quantitation of colonies per
well recovered from each of the four genotypes (n= 6 biological replicates for each genotype). Scale bars, 500 μM. b FASN mRNA and protein levels
detected in soft agar colonies recovered from the FASNlox/lox-PyMT and FASNΔ/Δ-PyMT MEFs, respectively. c Cell replication rates after 1, 2, or 3 days for
each genotype (n= 3). Presented data are the mean values ± standard deviation (SD). ***P < 0.001; n.s., not statistically significant; Student’s t test. d Flow
cytometry analysis of apoptosis. Percentages of cells in apoptosis are represented (FASNlox/lox-Empty, n= 7; FASNΔ/Δ-Empty, n= 8; FASNlox/lox-PyMT,
n= 7; FASNΔ/Δ-PyMT, n= 5). Presented data are the mean values ± standard deviation (SD)
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Lack of FASN product does not explain the transform failure.
The observed metabolic phenotype could impair transformation
for several reasons: (1) insufficient ATP production due to
decreased glycolytic and/or respiratory rates31; (2) insufficient
nucleotide production required for the DNA replication31; (3)
although cancer cells can incorporate fatty acids from the
surrounding media, the buildup of malonyl-CoA in the absence
of FASN could block fatty acid oxidation (FAO)51, a process
shown to be essential in certain malignancies such as MYC-
overexpressing breast cancer52; (4) the preferred source of pal-
mitate for cancer cells could be the endogenously synthesized
fatty acid by FASN. However, to our surprise, none of these four
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features found in the FASNΔ/Δ-PyMT MEFs were definitively
associated with the inability to transform. First, ATP levels and
ADP/ATP quotients were not significantly different between
FASNlox/lox-PyMT and FASNΔ/Δ-PyMT MEFs (Supplementary
Fig. 4a). Second, we attempted to rescue the ability of PyMT to
transform FASNΔ/Δ MEFs by adding dNTPs, and/or soraphen-A
[an acetyl-CoA carboxylase inhibitor that decreases the avail-
ability of malonyl-CoA pools53], and/or palmitate to the media
following the time points outlined in Supplementary Fig. 4b.
Interestingly, in the presence of palmitate, neither soraphen-A
nor dNTPs could rescue the transforming ability of PyMT in
FASNΔ/Δ MEFs (Supplementary Fig. 4c). FAO of exogenous,
14C-labeled fatty acids shows that both FASNlox/lox-PyMT and
FASNΔ/Δ-PyMT MEFs oxidize fatty acids, although FASNΔ/Δ-
PyMT MEFs do so—as expected—at a lower rate (Supplemen-
tary Fig. 4d). The addition of soraphen-A, as predicted, boosted
and rescued, respectively, FAO in FASNlox/lox-PyMT and
FASNΔ/Δ-PyMT MEFs (Supplementary Fig. 4e), suggesting that
although the malonyl-CoA buildup accounts for a decrease in
FAO, this is not the reason why FASNΔ/Δ-PyMT can not
undergo transformation. Taken together, these observations
indicate that although the lack of FASN affected several impor-
tant cellular functions, they were not the ultimate cause of the
failure to transform. In addition, this experiment showed that
transformation was only possible in fatty acid-containing media
(either free fatty acids (FFAs) or lipoproteins36), and that FAS-
Nlox/lox-PyMT-HER2 or PyMT-KRAS MEFs could not form
colonies in fatty acid-free media (Supplementary Fig. 4f). The
role of exogenous fatty acid in colony formation essentiality was
further tested: first, palmitate represents only 26% of fetal bovine
serum (FBS) fatty acid pools54; thus, other exogenous lipids
could be essential for transformation. When FASNlox/lox-PyMT,
FASNlox/lox-HER2, or FASNlox/lox-KRAS MEFs were incubated
in full medium with FBS and the fatty acid uptake inhibitor
sulfo-N-succinimidyl oleate (SSO)55, no colonies were recovered.
Second, when fatty acid-free media were supplemented with fatty
acid-free albumin-complexed palmitate in order to facilitate its
uptake by cancer cells, FASNlox/lox-PyMT, FASNlox/lox-HER2, or
FASNlox/lox-KRAS MEFs did not form colonies in soft agar
(Supplementary Fig. 4f). Last, tumor epithelial cells from the
breast of PyMT animals with (FASN+/+; PyMT) or without
(FASNΔ/Δ; PyMT) FASN displayed similar intracellular neutral
lipid accumulation evidenced by oil-red staining (Supplementary
Fig. 4g). These results indicate that fatty acid requirements of
cancer cells are mainly satisfied by the uptake from FFAs,
implying that FASN is required for transformation for a different
reason than its synthetic product.
Upregulation of FASN elicits the 2D-to-3D switch. Colony
formation assays and tumor formation in vivo require 3D growth
in the absence of extracellular matrix anchorage. Anchorage-
independent growth is a hallmark of cancer33. Detachment from
the matrix is associated with increased ROS production34. We
hypothesized that the lack of tumorigenicity observed in the
FASN-negative cells might be related to an insufficient capacity
for quenching excessive ROS32. Therefore, we studied cell cul-
tures under ultralow attachment conditions in which cancer cells
form 3D tumor colonies or spheroids and mimic soft agar
experiments, but allow easier experimental manipulation. In
contrast with the 2D experiments in which FASNΔ/Δ-PyMT and
FASNlox/lox-PyMT did not show significant differences in cell
replication, the cell number and the size of spheroids recovered
after 72 h of growth under ultralow attachment conditions of the
FASNΔ/Δ-PyMT MEFs were decreased in more than 75% com-
pared with FASNlox/lox-PyMT MEFs (Fig. 4a). Similar decreases
in spheroid formation were observed in HC11 and MEFs
expressing PyMT, KRAS, or HER2 when cells lacked FASN
(Supplementary Fig. 4a). This phenotype was accompanied by a
similar decrease in OCR as observed in 2D experiments (Fig. 4b).
Regarding ROS levels, FASNlox/lox-PyMT MEFs did not show
significant changes in the transition from 2D to 3D growth.
However, FASNΔ/Δ-PyMT experienced a >20-fold increase in
ROS in 3D compared with 2D conditions (Fig. 4c). Similar ROS
increases were observed in 3D compared with 2D for the HER2,
KRAS, and PyMT oncogenes in FASN-negative MEFs and
HC11 cells (Supplementary Fig. 4b).
Reportedly, ROS levels must be maintained within certain
boundaries to allow tumors to develop32. Thus, an excess of ROS
could account for the inability to transform in the absence of
FASN. In that case, forcing ROS production in FASNlox/lox-PyMT
MEFs should phenocopy FASN deletion. We treated FASNlox/lox-
PyMT MEFs cultured in 3D with 10 μM DMNQ (a cell-
permeable redox cycling quinone that produces intracellular
superoxide anion). At this dose level, DMNQ produced similar
ROS levels to those observed in FASNΔ/Δ-PyMT MEFs in 3D
(Fig. 4d). As expected, DMNQ disrupted spheroid formation
(Fig. 4e).
A recent report showed that in 2D cancer cultures, glutamine is
transformed into α-ketoglutarate via glutamate and then oxidized
along the Krebs cycle; however, in 3D cultures, glutamine-derived
α-ketoglutarate was produced in the cytosol and transformed into
isocitrate/citrate via IDH1-dependent reductive carboxylation39,40.
This pair of metabolites can be shuttled back into the
mitochondria and enter the Krebs cycle generating intra-
mitochondrial NADPH to quench the 3D ROS excess by
Fig. 2 FASN deficit impairs the upregulation of glycolysis and the anaplerotic shift of Krebs cycle. a The lack of FASN led to an accumulation of NADPH,
acetyl-, and malonyl-CoA. The increase in acetyl-CoA can allosterically inhibit the activity of pyruvate dehydrogenase. This can block the entry of pyruvate
into the Krebs cycle (associated with a decrease in the NAD-NADH cycling, respiration, and glycolytic rates) and the derivation of carbon skeletons to
biosynthetic routes. In addition, a decrease in Krebs cycle activity could be coupled to a limited ability to satisfy high energetic demands. Pyruvate
accumulation could also decrease glycolysis, which in addition to limiting ATP production would impair the ability to derive carbon skeletons to the
nucleotide synthesis pathways. All these processes are upregulated in transformed compared with normal cells and are a hallmark of cancer33. b Total
abundance of acetyl-CoA and NADPH determined by LC/MS across the four genotypes (n= 4). c Representative extracellular acidification rate (ECAR)
measurements. Glucose, oligomycin, and 2-deoxyglucose (2-DG) were added at the indicated time point for each experiment. d Mitochondrial respiration
reflected by oxygen consumption rate levels (OCR) was detected in the four genotypes. In c, d presented data are mean values ± SEM. e Mitotracker dye
(green) was used to reveal the localization of mitochondria (left), and the positively charged dye TMRE (red) (middle) was used to compare mitochondrial
transmembrane polarization. Representative fluorescence images of TMRE and Mitotracker were taken by confocal microscopy. Merged images are
shown. Scale bars, 10 μM. Quantitative analysis of relative fluorescence intensity is shown in the right-hand side (FASNlox/lox-Empty, n= 388 cells;
FASNΔ/Δ-Empty, n= 458 cells; FASNlox/lox-PyMT, n= 294 cells; FASNΔ/Δ-PyMT, n= 382 cells). FCCP was added to FASNlox/lox-PyMT as a negative
control (n= 90 cells). f Representative flow cytometry analysis (left) showing constitutive mitochondrial superoxide levels for each genotype (n= 4). The
quantitation of MitoSOX red fluorescence intensity is shown in the right. In b, e, and f represented data are the mean values ± SD. *P < 0.05, **P < 0.01, and
***P < 0.001; Student’s t test
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maintaining glutathione (GSH) levels40. Among the potential
effects derived from the lack of FASN catalytic activity, acetyl-CoA
accumulation could block the activity of ATP citrate lyase, leading
to a buildup of cytoplasmic citrate/isocitrate that would stall the
IDH1-dependent reductive carboxylation required for sustaining
3D growth. Although the citrate/isocitrate m+ 2 was reduced in
FASNΔ/Δ-PyMT (Fig. 3e), reflecting a decrease in pyruvate
dehydrogenase activity, the total citrate/isocitrate levels were
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unchanged (Fig. 3e). Concordantly, both the addition of sodium
citrate or SB204990 (an ATP-citrate lyase inhibitor) to the 3D
cultures of FASNlox/lox-PyMT phenocopied FASNΔ/Δ-PyMT
MEFs: (1) no spheroids were recovered (Fig. 4f); (2) ROS levels
were similar to those observed in FASNΔ/Δ-PyMT MEFs (Fig. 4f);
(3) OCR was suppressed (Fig. 4g). As expected, ATP citrate lyase
activity was significantly decreased in FASNΔ/Δ-PyMT MEFs
compared with FASNlox/lox-PyMT MEFs (Fig. 4h). Citrate and
SB204990 also disrupted spheroid formation and decreased OCR/
ECAR in FASNlox/lox MEFs or HC11 cells transformed with
KRAS, HER2, or PyMT (Supplementary Fig. 5a, b). In 2D growth,
MEF and HC11 cell viability was unaffected by the addition of
citrate or SB204990 at the concentration used in previous
experiments (5 mM and 30 µM in MEFs; 3 mM and 30 µM in
HC11, respectively; Fig. 4i, j, Supplementary Fig. 6c, d). When
IDH1 was silenced with small-interfering RNA (siRNA) (Supple-
mentary Fig. 10a) in 3D, it led to a disruption in the formation of
tumor spheroids (Supplementary Fig. 10b) and suppression of
OCR (Supplementary Fig. 10c) together with increased ROS
(Supplementary Fig. 10d), compared with no effect in these traits
in 2D. Taken together, these data suggest that in the absence of
FASN, citrate lyase activity is diminished, and this enzymatic
impairment is linked to a defect in 3D, but not 2D, tumor cell
growth.
Carbon-tracing experiments with [U-13C5]glutamine demon-
strated that in the absence of FASN, cells showed a decreased
ability to perform reductive carboxylation; however this limita-
tion was restricted to 3D growth (Fig. 5d–f) and not observed in
2D growth (Fig. 5a–c). Increased α-ketoglutarate m+ 5 and
fumarate m+ 4 labeling from [U-13C5]glutamine in FASNΔ/Δ-
PyMT MEFs under 2D conditions revealed that in the absence of
FASN, MEFs may compensate the decreased entry of carbon
skeletons from glucose into the Krebs cycle by enhancing the
oxidative metabolism of glutamine (Fig. 5a, b). In addition, no
changes in citrate/isocitrate m+ 5 levels were observed between
genotypes, indicating that glutamine enters the mitochondria and
participates predominately in oxidative metabolism (Fig. 5c).
However, in 3D, isotope tracing revealed that the reductive
formation of citrate/isocitrate m+ 5 from glutamine was
enhanced in FASNlox/lox-PyMT MEFs. This was observed only
in FASNlox/lox-PyMT MEFs, indicating active IDH1-dependent
reductive carboxylation (Fig. 5d, e, f). These data suggest that
IDH1-dependent reductive carboxylation is halted in FASNΔ/
Δ-PyMT MEFs. In this situation, theoretically, there would be
insufficient intra-mitochondrial reduced equivalents, which
would be consumed by the excess of unquenched ROS produced
during the 2D–3D transition. This would be followed by an
impairment of mitochondrial respiration that should be rescued
by the addition of reductive equivalents. To test this hypothesis,
first we measured intra-mitochondrial and total NADPH. Total
NADPH levels were decreased in FASNΔ/Δ-PyMT compared with
FASNlox/lox-PyMT MEFs (Fig. 5g). However, the difference was
more pronounced in the intra-mitochondrial compartment
(Fig. 5g), which is congruent with the fact that cytoplasmic levels
may still be high because of the lack of activity of FASN, which
consumes NADPH. It has been shown that an increased ROS
production could disrupt the assembly of mitochondrial com-
plexes into supercomplexes56,57, stalling respiration. While in 2D
the decreased respiration levels of FASNΔ/Δ-PyMT can be
attributed to a decreased entrance of pyruvate in the mitochon-
dria, in 3D the increased ROS might be a more important
contributor. In fact, we observed that in 2D total NADPH was
increased in FASNΔ/Δ-PyMT clones (Fig. 2b); however, in 3D in
the context of decreased citrate lyase activity, we observed
decreased intramitochondrial NADPH levels (Fig. 5g), increased
ROS (Fig. 4c), and a decreased proportion of complex I assembly
into supercomplexes (Fig. 5h). In order to ascertain the functional
impact of these observations, we cultured FASNΔ/Δ-PyMT MEFs
in the presence of either N-acetyl-cysteine (NAC) or glutathione
monoethyl ester (GSH-MEE), two ROS-quenching agents. This
approach rescued OCR (Fig. 5i), tumor spheroid formation, and
soft agar colony formation (Fig. 5j) while reducing ROS burden in
3D (Fig. 5k). The NAD+/NADH quotient was also restored after
the addition of NAC/GSH-MEE (Fig. 5l). We observed similar
rescues in the other studied FASN-negative systems expressing
different oncogenes (Supplementary Fig. 6a, b). Taken together,
our data suggest that the acetyl-CoA buildup secondary to FASN
deletion inhibits ATP citrate lyase and induces an accumulation
of citrate/isocitrate. Subsequently, this impairs IDH1-dependent
reductive carboxylation, a tumor cell requirement limited to 3D
growth, inducing a decrease in intramitochondrial NADPH, an
increase in ROS, and finally mitochondrial supercomplexes’
assembly disruption, which ultimately impairs cell transformation
and tumorigenesis.
FASN deletion prevents formation of invasive tumors. In vivo,
the PyMT oncogene expressed under the control of the MMTV
promoter in a pure FVB background generates invasive ductal
carcinoma of the breast that recapitulates human “luminal-B”
tumors in ~100% of the animals at the age of 7 weeks58. Figure 6a
shows FASN staining in breast sections of wild-type and MMTV-
PyMT animals at 4, 8, and 13 weeks of age. This time course
shows that FASN upregulation is associated with tumor devel-
opment. We crossed FASNlox/lox;Tg UBC-CreERT2 mice with
MMTV-PyMT animals and induced systemic Cre activity with
tamoxifen when animals were weaned off (4–5 weeks of age).
Tamoxifen was also administered to the control group. Impor-
tantly, FASN+/+; PyMT and FASNΔ/Δ; PyMT animals showed
similar fasted triglyceride blood levels (Supplementary Fig. 7a).
The PyMT is an extraordinarily penetrant oncogene (hundreds of
tumor foci are simultaneously developed in each mammary
gland), and Cre recombinase activity was not sufficient to delete
the FASN gene in 100% of the breast epithelial cells (Fig. 6b), thus
allowing the development of FASN-positive tumor foci. However,
FASN-negative regions did not develop breast tumors (Fig. 6b).
Based on our previous in vitro data, an insufficient capacity for
Fig. 3 Decreased glucose carbon flux and the pentose phosphate pathway. a Schematic representing incorporation of 13C derived from glucose into
metabolites of glycolysis and the Krebs cycle. White and black circles are 12C and 13C, respectively. b Decreased labeled but similar total palmitate pools in
FASNΔ/Δ-PyMT MEFs compared with FASNlox/lox-PyMT MEFs. 13C-NMR spectrum showing the central peak (singlet) at 14.17 p.p.m. characteristic of the
terminal methyl group (–CH3 or omega-1 carbon) of a fatty acid, and lateral peaks (doublet signal) corresponding to the penultimate –CH2- (or omega-2
carbon) due to 13C–13C coupling. c Isotopolog abundance of glucose-6-P (determined by LC/MS) and lactate (determined by RMN). d Glut1 and Glut4
glucose transporter mRNA levels determined by RT-qPCR, relativized to FASNlox/lox-PyMT values. The experiment was repeated three times. e Total
abundance of citrate/isocitrate and % labeling of citrate, aconitate, fumarate, and malate isotopologs in MEFs labeled with [U-13C]glucose (determined by
LC/MS) (n= 5 biological replicates), and f % labeling of –CH2 succinate isotopomer (determined by RMN) (n= 5 biological replicates). g Isotopolog
abundance of ADP ribose and AMP determined by LC/MS in FASNlox/lox-PyMT and FASNΔ/Δ-PyMT MEFs (n= 5 biological replicates). Presented data
are the mean values ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001; n.s., not statistically significant; Student’s t test
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quenching excess ROS might be related to the lack of breast
tumor development in FASN-negative regions in PyMT animals.
By using an oxidative damage DNA biomarker, anti-8-oxo-dG
that specifically binds to 8-oxo-2′-deoxyguanosine (8-oxo-dG),
one of the major products of DNA oxidation, we showed an
increase in ROS levels in FASNΔ/Δ; PyMT tumors (Fig. 6c).
Interestingly, this ROS accumulation in vivo corresponds to
FASN-negative areas evidenced by the detection of FASN and 8-
oxo-dG co-staining with monoclonal antibodies (Abs)59 (Fig. 6d).
The Kaplan–Meier curve shown in Fig. 6e depicts the differences
in time to killing between FASN+/+; PyMT and FASNΔ/Δ; PyMT
animals. Tumor volume is depicted in Fig. 6f. FASNΔ/Δ; PyMT
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animals ultimately also die due to the incomplete deletion of
FASN in the mammary tissue and development of PyMT/FASN-
positive tumors (although the number of tumor foci is smaller in
FASN-negative tumors, a single focus is sufficient to generate a
tumor that will mandate animal killing; Fig. 6b, arrows). In order
to achieve complete abrogation of FASN activity, we combined
genetic plus pharmacologic approaches. G28UCM is a compound
with FASN inhibitory properties27. Although this compound is
not clinical grade, it has been used to inhibit FASN effectively in
preclinical experiments. In vitro, G28UCM recapitulated the
main features of FASN deletion and showed moderate on-target
effect (Supplementary Fig. 8a–d). In vivo, when applied to
FASNΔ/Δ; PyMT animals, G28UCM induced further tumor
growth arrest; however, the combination was quite toxic and the
experiment had to be interrupted after 3 weeks. It has been shown
that FASN deletion in the intestinal epithelium can be lethal18.
FASN deletion by using UBC-CreERT2 was incomplete and
the animals tolerated it; however, in combination with G28UCM,
the animals suffered from intense diarrhea and weight loss akin
the intestinal FASN deletion study; Supplementary Fig. 8e. In
addition, in agreement with the proposed mechanism of action of
FASN deletion, when G28UCM was applied to FASNlox/lox;
PyMT animals, their tumors displayed intense 8-oxo-dG staining
(Supplementary Fig. 9).
We also tested the in vivo effects on tumor growth of FASNΔ/Δ
MEFs infected with KRAS or HER2, grafting them into wild-type
animals compared with FASNlox/lox counterparts (Supplementary
Fig. 7b, c). In line with the in vitro data (Supplementary Fig. 2g),
we did not observe different replication levels (Ki67 staining)
(Supplementary Fig. 7f) or oncogene levels (KRAS, HER2) in
tumors originated from FASNlox/lox or FASNΔ/Δ clones (Supple-
mentary Fig. 7g, h). A strong reduction in tumor growth was
observed. Finally, when HC11 cells with CRISPR-deleted FASN
were infected with PyMT or KRAS and grafted into wild-type
animals, a delay on tumor onset was observed compared with
wild-type counterparts (Supplementary Fig. 7d, e). Importantly,
the positive antitumor effects observed in these xenografts
were produced in a FASN wild-type background in the rest of
the organism, supporting the concept that the effects observed in
the PyMT model were independent of systemic FASN deletion.
Taken together, in vivo and in vitro data suggest that FASN is
essential for cell transformation and tumor development. We
investigated a potential cancer prevention role of FASN
inhibitors. Based on our data, this approach should be effective
at the preventive stage. Continuous G28UCM treatment admin-
istration from 5 weeks of age in MMTV-PyMT animals
significantly delayed tumor onset and growth (Fig. 7a).
Concordantly, G28UCM treatment also had an impact on the
overall survival of mice (Fig. 7b). Animals did not lose weight
during treatment (Fig. 7c). Although animals treated with
G28UCM experienced tumor development, histological analysis
showed that these tumors did not acquire the invasive, malignant
phenotype, and growth was limited to in situ ductal carcinoma.
The immunohistochemical staining shown in Fig. 7d depicts how
FASN staining was intense in both vehicle- and G28UCM-treated
tumors; however, collagen IV staining (a staining against the most
abundant collagen molecule present in the basement membrane
of breast gland ducts and used in the clinical setting to distinguish
invasive from in situ carcinomas) showed that although epithelial
cells proliferated and obliterated the ducts in the latter, the
basement membrane preserved its integrity in contrast with the
architecture-disrupting pattern observed in vehicle-untreated
animals. Based on these results, FASN inhibitors show potential
for tumor prevention when a clinical-grade compound becomes
available.
Discussion
FASN has been extensively studied in cancer, but its specific
mechanistic relationship with carcinogenesis, and its definitive
therapeutic role, have not been completely established. In the
present study, the role of FASN during transformation was
investigated and several significant results were found.
First, conceptually, disrupting metabolic events essential for
transformation could be more critical in clinical care (cancer
prevention) than after the cancer has already developed (cancer
therapeutics) when it can rely on different backup processes, and
has already overcome several rate-limiting steps of tumorigenesis.
Based on our data, FASN is essential for PyMT-mediated trans-
formation. MEF data, where the efficiency of adeno-Cre was
>95% and all the colonies recovered from the FASN-floxed clones
were the result of the residual adenoviral infection inefficiency
(Fig. 1b), clearly support this statement. The regional distribution
of FASN deletion achieved in vivo also supports that in the
absence of FASN, the breast epithelium cannot undergo trans-
formation (Fig. 6b). A recently developed acetyl-CoA carboxylase
inhibitor60 that blocks the generation of malonyl-CoA, a rate-
limiting step of fatty acid synthesis, has showed impressive
antitumor effects; several FASN inhibitors have achieved similar
results, although most compounds have significant off-target
effects26,27,29,30. However, antitumor efficacy has proven to be
always transient and tumors always regrow; thus, curing tumors
by using this strategy seems unlikely. From the clinical point of
view, the effects of targeting FASN before rather than after
transformation can only be emphasized.
Fig. 4 FASN deletion leads to ATP citrate lyase (ACLY) inhibition, blocking 3D growth. a Representative pictures of the spheroids recovered from the
different genotypes growing under ultralow attachment conditions for 72 h (left). Spheroid diameter (n= 30 spheroids, FASNlox/lox-PyMT; n= 24
FASNΔ/Δ-PyMT) and number of cells over 72 h (right). Scale bars, 500 μM. Presented data are the mean values ± SD. ***P < 0.001; Student’s t test. b OCR
assay performed with cells recovered from the previous experiment and monolayer cultures. Oligomycin, FCCP, and antimycin/rotenone were added at the
indicated time point. Data are represented as the means ± SEM. c Representative flow cytometry analysis showing constitutive mitochondrial superoxide
levels in monolayer compared with 3D conditions in PyMT MEFs loaded with MitoSOX Red (FASNlox/lox-PyMT, n= 4; FASNΔ/Δ-PyMT, n= 5). The
quantification of MitoSOX Red fluorescence intensity is shown on the left. Presented data are the mean values ± SD. ***P < 0.001, Student’s t test.
d Quantification of MitoSOX Red fluorescence intensity by flow cytometry analysis in FASNlox/lox-PyMT, FASNΔ/Δ-PyMT, and DMNQ-treated (10 μM;
20min) FASNlox/lox-PyMT MEFs (n= 3). e Effect of 10 μM DMNQ treatment in the ability of FASNlox/lox-PyMT MEFs to form spheroids. Scale bars,
500 μM. Representative pictures for each condition are shown. f Representative pictures showing the effects of sodium citrate (5 mM) or SB204990
(30 μM) in the formation of tumor spheroids by FASNlox/lox-PyMT MEFs. Scale bars, 500 μM. The lower charts show an increase in ROS production by
sodium citrate and SB204990. Representative flow cytometry analysis was shown (n= 4). g Effects in OCR suppression caused by sodium citrate or
SB204990 treatment in FASNlox/lox-PyMT MEFs. Presented data are the mean values ± SEM. Three independent experiments (h) ACLY activity in
FASNlox/lox-PyMT versus FASNΔ/Δ-PyMT MEFs. i, j Cell viability was determined in FASNlox/lox-PyMT MEFs at 24, 48, and 72 h in the presence of various
concentrations of SB204990 (n= 8) (i) or sodium citrate (n= 7) (j) under 2D culture conditions. In h–j represented data are the mean values ± SD. *P <
0.05, **P < 0.01, and ***P < 0.001; Student’s t test
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A very important finding from this study is that the impor-
tance of FASN for cancer development is independent of its
biosynthetic product. Previous studies relied on the assumption
that blocking FASN activity would limit the fatty acid pools
available for building different cellular membranes required for
proliferation1,37,38. While this effect may be important, our data
showed that in the pre-transformation state, re-supplementation
with palmitate and fatty acids did not rescue the phenotype
caused by FASN loss, indicating a different implication of FASN
in the carcinogenesis process. Adult mammals rely mostly on
dietary fatty acids to maintain peripheral fatty acid pools.
Therefore, the unchanged levels of blood fatty acids observed in
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the FASNΔ/Δ; PyMT mice compared with FASN+/+; PyMT mice
(Supplementary Fig. 7a) and the absence of tumor formation in
wild-type animals grafted with FASN-negative KRAS-, HER2-, or
PyMT-expressing cells (Supplementary Fig. 7b–e) show that the
observed abrogation of breast epithelium transformation is not
secondary to systemic effects of FASN deletion, and the avail-
ability in blood of the product that FASN synthesizes does not
rescue the transforming phenotype. The product-independent
role of FASN is further supported by the following facts: (1) in 2D
conditions, FASNΔ/Δ-PyMT MEFs grow normally (Fig. 1c) but
not in 3D conditions (Fig. 4a); (2) palmitate or FFA-free albumin-
complexed palmitate do not rescue tumorigenesis in FASNΔ/
Δ-PyMT MEFs (Supplementary Fig. 4c, f); (3) the preferential
source of fatty acids appears external, and maybe relying on fatty
acids different from palmitate, evidenced by FASNlox/lox-PyMT
MEFs with intact FASN levels forming colonies only in the pre-
sence of fatty acids in the media, but losing the ability to form
colonies in the presence of SSO (Supplementary Fig. 4f). Data
from the measurement of unlabeled lipid pools in both genotypes
(Fig. 3b) and neutral lipid accumulation in the tumor epithelium
of PyMT animals (Supplementary Fig. 4g) further support this
conclusion. Although the lack of FASN affected several other
metabolic pathways associated with transformation31 (Fig. 2a), it
did not account for the inability to transform cells as evidenced
by the reconstitution experiments.
Finally, probably the most relevant finding is the role of FASN
facilitating the transition from 2D to 3D growth. In normal cells,
the main function of FASN is long-chain fatty acid synthesis;
however, transforming cells can harness this enzymatic reaction
to support transformation by eliciting the acquisition of a hall-
mark of cancer, 3D anchorage-independent growth33. In the
absence of FASN, the production of reduced equivalents from
IDH1-dependent reductive carboxylation to quench the excessive
ROS observed in the 2D–3D transition is impaired, which leads to
the observed decrease in intra-mitochondrial NADPH (Fig. 5g),
and decreased levels of mitochondrial complex I assembly into
supercomplexes (Fig. 5h), which accounts for the inability to
transform (Figs. 4 and 5). This was proven by carbon tracing,
enzymatic activity determination, ROS levels, mitochondrial
complex integrity analysis, and phenocopying/phenotype-rescu-
ing experiments with several metabolites and inhibitors across
several different genotypes. Excessive ROS were observed in
FASNΔ/Δ; PyMT animals in the FASN-negative PyMT-positive
areas that proliferate but did not acquire invasive growth prop-
erties (Fig. 6d). Similarly, when G28UCM was administered
in vivo, invasive growth was not observed (Fig. 7d). Based on our
data, FASN would be a necessary checkpoint for the acquisition
of this essential hallmark of cancer.
FASN has been previously related to relevant diverse features
of tumor progression such as increased cell replication1 or
HER2 signaling61. In the present study, we described a
mechanism regarding the role of FASN in cancer, linking the very
common upregulation of FASN in cancer to a critical role in
acquiring 3D growth properties during transformation, unrelated
to its biosynthetic product. Because endogenous FASN is not
required in most adult tissues and due to the specificity of the
IDH1-dependent reductive carboxylation process in cancer cells,
this mechanism is a highly attractive, cancer-specific target. With
novel FASN inhibitors in perspective30,62,63, a clinical-grade
compound that would selectively target FASN could be admi-
nistered long term to a healthy individual, by sparing toxicity to
normal tissues, while it could target cells in their initial steps of
transformation. Taken together, these features indicate that FASN
is a potential target for cancer prevention. Future studies with
clinical-grade compounds in high-risk patient subpopulations
(akin previous chemoprevention trials in breast cancer64,65) could
address the therapeutic utility of this strategy.
Methods
Generation of FASN-knockout mice. FASNlox/lox mice were generated from
knockout embryonic stem (ES) cells for FASN (C57BL/6N-FASN tm1(KOMP)wtsi)
obtained from the KOMP Repository (www.komp.org) (KOMP Repository, UC
Davies)66. ES cells were microinjected into C57BL/6 mouse blastocysts, from which
chimeric males were obtained. Chimeras were bred with C57BL/6 wild-type
females to produce heterozygous floxed (FASNflox/+) mice.
After successful germ line transmission, FASNflox/+ mice were crossed with Flp
transgenic mice to facilitate in vivo frt-neo deletion (FASNlox/+). To obtain FASNlox/
+ mice with the FVB background, we backcrossed FASNlox/+ heterozygous males
with FVB females by using marker-assisted selection protocol (Speed Congenics). At
every generation, the mouse carrying the fewest C57BL/6 background loci was used
for backcrossing. After six generations, a close to 100% of FVB background was
achieved. Then, FASNlox/lox mice were bred with Cre recombinase-expressing
transgenic mice to achieve deletion of the targeted region. Tg-UBC-CreERT241 were
obtained from the CNIO Animal House (Madrid, Spain). PyMT [FVB/N-Tg
(MMTV-PyVT634Mul/J)] mice were obtained from W. Muller (McMaster University,
Ontario, Canada). All mice were on a FVB pure background with littermate controls
(females) used in all experiments. Genotyping was performed by PCR analysis of tail
DNA. Primers used for genotyping FASN wild-type (wt) and floxed mice were
common forward (5′-ATGGATTACCCAAGCGGTCT-3′) and common reverse (5′-
CCTGTCTCTGAGCCCTTGAT-3′). Polymerase chain reaction conditions were as
follows: 95 °C for 15min; 94 °C for 30 s; 35 cycles at 57 °C for 30 s; 72 °C for 30 s;
72 °C for 10min; then soaking at 4 °C. Primers used for genotyping Cre allele were
forward—5′-GCTCGACCAGTTTAGTTACCC-3′ and reverse—5′-
TCGCGATTATCTTCTATATCTTCAG-3′. Polymerase chain reaction conditions
were as follows: 95 °C for 15min; 94 °C for 30 s; 35 cycles at 64 °C for 30 s; 72 °C for
30 s; 72 °C for 10min; then soaking at 4 °C. Primers used for genotyping PyMT
transgene were 5′-GGAAGCAAGTACTTCACAAGG-3′ and 3′-GGAAA
GTCACTAGGAGCAGGG-5′. Polymerase chain reaction conditions were as follows:
95 °C for 15min; 94 °C for 30 s; 30 cycles at 59 °C for 45 s; 72 °C for 1 min; 72 °C for
10min; then soaking at 4 °C. PCR products are 336 bp (base pair) for wt allele,
438 bp for lox allele, 470 bp for cre allele, and 557 bp for PyMT allele.
Fig. 5 FASN deficit leads to an impairment of IDH1-dependent reductive carboxylation. a Isotopolog abundance of α-ketoglutarate, b fumarate, and c and
citrate/isocitrate from [U-13C5]glutamine in 2D cultures determined by LC/MS (n= 4 biological replicates). d Isotopolog abundance of α-ketoglutarate,
e fumarate, and f citrate/isocitrate from [U-13C5]glutamine in 3D cultures determined by LC/MS (n= 4 biological replicates). Presented data are the mean
values ± SD. *P < 0.05; Student’s t test. g Relative levels of NADPH in cellular and mitochondrial lysates of FASNlox/lox-PyMT versus FASNΔ/Δ-PyMT MEFs
in 3D cultures (n= 3). Presented data are the mean values ± SD. *P < 0.05 and ***P < 0.001; Student’s t test. h Digitonin-solubilized isolated mitochondria
from FASNlox/lox-PyMT and FASNΔ/Δ-PyMT MEFs in 2D and 3D culture conditions were subjected to blue native gel electrophoresis (BNGE) followed by
in-gel complex I activity assay. Complex I occurs both free and bound with complex III (I+ III2 and I2+ III2 supercomplexes). Relative abundance of
assembled complex I into supercomplexes (SC) versus free complex I (CI) after the quantification of band intensity in direct immunobloting of BNGEC
against complex I subunit NDUFS1 in FASNlox/lox-PyMT versus FASNΔ/Δ-PyMT in 2D and 3D culture conditions is shown. Presented data are the mean
values ± SD (n= 2 independent culture preparation). *P < 0.05; Student’s t test. i NAC (1 mM) and GSH-MEE (1 mM) rescue experiments. Data are
represented as mean values ± SEM. Three independent experiments. j Rescue of soft-agar colonies (above) and spheroids (below) in FASNΔ/Δ-PyMT
MEFs treated with NAC (1 mM) or GSH-MEE (1 mM). Representative images for each condition are shown. Scale bars, 500 μM. k Representative flow
cytometry analysis showing constitutive mitochondrial superoxide levels in FASNΔ/Δ-PyMT MEFs treated with NAC or GSH-MEE (n= 4). MitoSOX red
fluorescence intensity quantitation is shown on the right. Presented data are the mean values ± SD. **P < 0.01; Student’s t test. l NAD+/NADH ratio is
restored after the addition of NAC or GSH-MEE in FASNΔ/Δ-PyMT MEFs in 3D cultures (n= 4). Presented data are the mean values ± SD. *P < 0.05;
Student’s t test
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Cell lines’ generation and treatments. MEFs were isolated from FASNlox/lox
embryos (embryos were collected at E12.5). MEFs were grown in Dulbecco’s
minimum essential media (DMEM, Invitrogen) supplemented with 10% FBS
(Sigma) and antibiotics (Sigma) in a humidified incubator at 37 °C with 5% CO2.
For immortalization, cultures were retrovirally transduced with SV40 T antigen (in
vectors pBABE-hygromycin kindly provided by Manuel Serrano, Spanish National
Cancer Research Centre, Madrid). For genetic deletion of FASN, FASNlox/lox MEFs
were infected with adeno-Cre (Gene Transfer Vector Core, University of Iowa).
Empty adenoviruses (Gene Transfer Vector Core, University of Iowa) were used as
a control. MEFs were incubated for 24 h at 37 °C with a reduced volume of culture
medium containing the virus at the appropriate concentration, and then refed with
fresh medium. Three days post infection, MEFs were used for oncogenic trans-
formation experiments.
HC11_FASN-knockout cells were generated by using the CRISPR/Cas9 All-in
One Lentivector System (Applied Biological Materials). Briefly, recombinant
lentiviruses were generated in HEK293T cells by co-transfection of 5 µg of single-
guide RNA (sgRNA)-encoding plasmids targeting mouse FASN (Cat#K3717105)
or scrambled sgRNA (Cat#K010) with 2.5 µg of pVSV-G and 2.5 µg of psPAX2
packaging plasmids (Addgene) with 750 µL of Opti-MEM that contained 30 µL of
Lipofectamine 2000 (Sigma). After 48 h, HC11 mammary epithelium cells (ATCC,
CRL-3062) were infected, and stable integrants were selected with puromycin
(2 μg/mL). HC11 cells were grown in RPMI-1640 medium (Invitrogen)
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supplemented with 10% FBS (Sigma) and antibiotics (Sigma) in a humidified
incubator at 37 °C with 5% CO2. For oncogenic transformation experiments, MEFs
and HC11 cells were retrovirally transduced with empty (EV), PyMT (kindly
provided by Erwin Wagner, Spanish National Cancer Research Centre, Madrid),
KRAS (G12D), or HER2 (A775_G776insYVMA)-containing pBABE-puromycin or
pBABE-hygromycin vectors as required. Retroviral infections were done by using
standard procedures, and infected MEFs and HC11 cells were selected with
puromycin (2 μg/mL) or hygromycin (150 µg/mL) as required for at least 5 days.
Dishes with ultralow attachment surface (Corning) were used for suspension
and spheroid culture. Identical culture medium was used for monolayer and
spheroid culture. For spheroids, 3 × 105 cells were plated in a 10-cm ultralow
attachment dish. For rescue experiments, NAC (Sigma) 1 mM, GSH-MEE, a
membrane-permeable derivative of GSH (Santa Cruz) 1 mM, dNTP 100 μM (four
deoxynucleotides: dATP, dCTP, dGTP, and dTTP, each at a concentration of 100
mM) (Sigma), soraphen A 200 nM (soraphen A was kindly provided by Dr. Mark
Brönstrup, Helmholtz Centre for Infection Research, Braunschweig, Germany), or
palmitate 0.5 mM (Sigma) were added to the media 24 h after adeno-Cre infection
in monolayer cultures. Sodium citrate (Sigma) or SB204990 (Tocris) was added to
the media before PyMT, KRAS, and HER2 overexpression in monolayer cultures.
For DMNQ (Sigma) treatment, 10 μM was directly added to FASNlox/lox-PyMT
MEFs in 3D cultures. To assess the role of exogenous fatty acid in colony formation
essentiality first, full medium with FBS was supplemented with the fatty acid
uptake inhibitor SSO (25 μM). Second, media was supplemented with 10% fatty
acid-free bovine serum albumin (BSA) (Sigma) instead of FBS. Third, cells were
treated with FFA-free BSA–palmitate (0.2 mM) conjugate (1:6 molar ratio) in cell
culture medium. Spheroid size was determined by measuring the maximum cross-
sectional area of individual spheroids by using ImageJ software.
Animal experiments. All animal experiments were approved by the Instituto de
Salud Carlos III Ethics Committee (PROEX 387/15) and performed in accordance
with the guidelines stated in the International Guiding Principles for Biomedical
Research Involving Animals developed by the Council for International Organi-
zations of Medical Sciences. For spontaneous tumorigenesis studies, FASN+/+;
Cre+; PyMT+ and FASNlox/lox;Cre+; PyMT+ females were fed tamoxifen diet
(Envigo) at 5 weeks of age for early FASN deletion. For the animal treatment,
G28UCM was dissolved in 10% dimethyl sulfoxide/90% phosphate-buffered
saline (PBS) solution and administered by intraperitoneal injection at the dose of
40 mg/kg per day starting at 5 weeks of age. Body weight was registered weekly.
Tumor formation and growth were monitored weekly by using calipers.
Four- to 6-week-old female athymic nude mice (Hsd: athymic nude-Foxn1nu)
were purchased from Charles River Laboratories. For mammary fat pad injections,
2 × 106 cells were resuspended in 50% Matrigel (Corning) and injected (50-μl
volume) into female mammary fat pads. Tumor formation and growth were
monitored weekly by using calipers. Tumor volumes were calculated by using the
formula V= (D × d2)/2 mm3, where D is the largest diameter and d is the shortest
diameter. Mice were euthanized in a CO2 chamber when reaching humane end
point (1500 mm3). Tumors were dissected from the front limb mammary fat pad
and fixed (10% formalin solution) for histological examination (formalin-fixed
paraffin-embedded). % Tumor growth was calculated by using the following
formula: % Tumor growth= [1−(TF/T0)A/(TF/T0)V] × 100, where TF is the time
point analyzed, T0 is the initial time, A is the tumor measurement corresponding to
FASNΔ/Δ; PyMT mice, and V is the tumor measurement from FASN+/+;
PyMT mice.
Cell viability assay. For cell viability assays, FASN+/+-PyMT MEFs and
HC11 cells were seeded (5 × 103 cells/well) in 96-well plates for 24 h and subse-
quently replaced with fresh medium with vehicle (control) or increasing con-
centration of sodium citrate (Sigma) (1, 2.5, 5.0, and 10 mM) or SB204990 (Tocris
Bioscience) (10, 20, 30, 40, 60, and 100 μM). Viability assays were performed in
triplicates. After 24, 48, and 72 h, cell viability was analyzed by using CellTiter-Glo
Luminescent Cell Viability Assay (Promega) following the manufacturer’s
instructions.
Soft-agar assay. Anchorage-independent growth was tested as follows: a base
layer of 0.9% agar in complete medium (DMEM plus 10% FBS) was plated in six-
well plates and allowed to solidify. Next, wells were overlaid with 15 × 104 cells per
well in a 0.4% agar. The plates were incubated at 37 °C, 5% CO2 for 3–4 weeks and
checked every 2–3 days for colony formation. Colonies were counted in the entire
dish by using a microscope.
Immunohistochemistry. For routine histological analysis, tissues were fixed in
10% buffered formalin (Sigma) and embedded in paraffin. Immunohistochemical
staining was performed on 3- to 4-μm paraffin sections. Immunohistochemistry
was performed by using an automated protocol developed for the DISCOVERY
XT-automated slide-staining system (Ventana Medical Systems Inc.). All steps
were performed on this staining platform by using validated reagents, including
deparaffinization, antigen retrieval (cell conditioning), and Ab incubation and
detection. Anti-FASN primary Ab (1:50, clone C20G5; 3180, Cell Signaling), anti-
collagen type IV Ab (1:250, CL50451AP; Cederlane), anti-Ki67 Ab (clone MIB-1,
M7240, Dako), anti-pan-RAS Ab (1:750, clone Ab-3; OP40, Merck), and anti-
HER2 (c-erB2) Ab (1:400, clone SP495; E12424, Spring Bioscience) were optimized
to identify optimal conditions for cell conditioning, dilution, incubation, and
detection. Localization of the primary Abs was accomplished by using an appro-
priate biotinylated secondary Ab, followed by incubation with
streptavidin–horseradish peroxidase and diaminobenzidine system. Slides were
digitalized and analyzed by using the ZEISS Zen 2.3 Imaging Software (Zeiss).
Western blotting. Cells were washed 2× with PBS and harvested in cold radio-
immunoprecipitation buffer (Sigma) containing 1% protease and phosphatase
inhibitor cocktail (Halt EDTA-free; Thermo Scientific). Cell lysates were incubated
at 4 °C for 15 min, sonicated for 15 min, and clarified by centrifugation at 14,000 ×
g at 4 °C for 30 min. Protein concentration was estimated by a colorimetric assay
(660-nm protein assay; Pierce) following the manufacturer’s instruction. Twenty
micrograms of proteins per sample were loaded on 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis gel and transferred to nitrocellulose membranes
for further processing. Five percent of BSA was used to block the membrane for
60 min at room temperature, followed by overnight incubation at 4 °C with the
primary Abs. The following primary Abs were used: FASN (1:1000, clone: C20G5;
3180, Cell Signaling), PyMT (1:2500, NB100-2749, Novus Biological), K-Ras
(1:1000, clone: F234; sc-30; Santa Cruz), HER2 (1:1000, 2242, Cell Signaling), IDH1
(1:1000, clone: D2H1, 8137, Cell Signaling), β-actin (1:5000, clone AC-15; A5441,
Sigma), γ-tubulin (1:2500, clone GTU-88; T6557, Sigma), and vinculin (1:2000,
clone: hVIN-1; V9131, Sigma). Membranes were incubated with appropriate
peroxidase-conjugated secondary Abs (Sigma). Bands were visualized by the
enhanced chemiluminescence method (Lumi-LightPlus Detection Kit; Roche). The
ImageJ software was used to compare the density of bands. The uncropped and
unprocessed scans of the blots were provided in Supplementary Fig. 11.
Immunofluorescence. Immunohistofluorescence was performed on formalin-fixed
mouse tissues. Five-micrometer paraffin-embedded sections were deparaffinized
and rehydrated in graded alcohol series. After rehydration, the paraffin sections
were boiled in a microwave oven for epitope retrieval in sodium citrate buffer
(10 mM [pH 6]) for 15 min. Sections were equilibrated in water and incubated with
blocking solution (5% normal goat serum in TBS-T [Tris-buffered saline with
Tween-20]) for 1 h at room temperature. Later it is washed with 1× PBS and
Fig. 6 fects of FASN deletion in tumor development. a FASN-stained slides from wild-type and MMTV-PyMT FVB mice mammary pads at weeks 4, 8, and
13. FASN is expressed in the cytoplasm of adipocytes (asterisks) in wild-type animals. A weaker FASN expression was observed in breast epithelial ducts
(arrows). Conversely, FASN upregulation was observed in the proliferating ducts (week 4), invasive carcinomas arising from the ducts (week 8), and fully
developed tumors (week 13) in the MMTV-PyMT animals. Scale bars, 100 μM. b Representative images of sections of the mammary pad of FASN+/+;
PyMT and FASNΔ/Δ; PyMT animals stained for FASN. The areas negative for FASN have normal or at most proliferative (but not invasive) ducts
(asterisks). Invasive growth was only observed in the FASN-positive areas of the FASNΔ/Δ; PyMT mice (arrows). Scale bars, 200 μm (low magnification)
and 100 μm (high magnification; i, ii, iii). c Representative fluorescent images of DAPI (blue) and 8-oxo-deoxyguanosine (8-oxo-dG) (red) staining of
mammary pad sections of FASN+/+; PyMT and FASNΔ/Δ; PyMT animals. Merged images are shown. The quantification of cellular 8-oxo-dG fluorescence
intensity in breast tumors is shown on the right (FASN+/+; PyMT, n= 4500 cells; FASNΔ/Δ; PyMT, n= 6500 cells). Presented data are the mean values ±
SD. ***P < 0.001; Student’s t test. Scale bars, 50 μM. d Representative fluorescent images of DAPI (blue), FASN (green), and 8-oxo-dG (red) co-staining of
mammary pad section of FASNΔ/Δ; PyMT animals. Scale bars, 50 μM. e Time to killing due to loco-regional tumor growth of FASN+/+; PyMT (n= 43) and
FASNΔ/Δ; PyMT (n= 44) animals; survival is increased from 90 to 123 days (log-rank P < 0.0001). f Tumor volume evolution in FASN+/+; PyMT (n= 43)
and FASNΔ/Δ; PyMT (n= 44) animals. Representative tumor burden charts at T4, T5, and T6 weeks (since treatment initiation) are shown below the
survival curve (T4: FASN+/+; PyMT n= 42, FASNΔ/Δ; PyMT n= 16; T5: FASN+/+; PyMT n= 41, FASNΔ/Δ; PyMT n= 15; T6: FASN+/+; PyMT n= 40,
FASNΔ/Δ; PyMT n= 15). Presented data are the mean values ± SEM. ***P < 0.001; Student’s t test
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Fig. 7 FASN inhibition prevents the development of invasive ductal carcinoma. a Inhibitory effects of G28UCM on tumor growth in MMTV-PyMT animals.
Presented data are the mean values ± SEM (n= 11 mice per group). ***P < 0.001; Student’s t test. b Kaplan–Meier survival curves of mice treated with
either vehicle (n= 11 mice) or G28UCM agent (n= 11 mice). Survival was calculated from the time of treatment initiation. Survival is increased in
G28UCM-treated mice from 40 to 49 days (log-rank P < 0.01). c Average animal weight during vehicle (n= 11 mice) or treatment (n= 11 mice). d Upper
panels: FASN staining in vehicle- or G28UCM-treated breast tumors. Lower panels: collagen IV staining (basement marker) reveals that G28UCM-treated
MMTV-PyMT animals develop only noninvasive ductal in situ carcinoma proliferations. Representative images were obtained for each treatment. Scale
bar, 500 μm
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incubated with anti-8-oxo-dG Ab (1:250, clone: 2E2; 4354-MC-050, Trevigen) at a
concentration of 1:250 at 4 °C o/n in a humidified chamber. Sections were washed
twice in TBS-T for 10 min and incubated with Alexa Fluor 594 donkey anti-mouse
immunoglobulin G (IgG) (1:200; Thermo Fisher Scientific) secondary Ab for 1 h at
room temperature. Sections were counterstained with DAPI (4′,6-diamidino-2-
phenylindole) and mounted in ProLong Gold antifade reagent (Life Technologies).
Digital images were taken by a TCS SP5 confocal microscope (Leica Microsystems)
at a resolution of 757.6 nm/px. Images were captured by using a ×20/0.7NA dry
objective, and the optical section was 3.665 μm. Images were analyzed with Defi-
niens Developer XD software with a customized script for detection and intensity
quantification. For immunofluorescence double staining with anti-FASN and anti-
8-oxo-dG, paraffin sections were incubated with rabbit anti-FASN (dilution 1:50,
Cell Signaling) and mouse anti-anti-8-oxo-dG (1:250, Trevigen) at 4 °C o/n in a
humidified chamber. Sections were washed twice in TBS-T for 10 min and incu-
bated with Alexa Fluor 488 goat anti-mouse IgG (1:200; Thermo Fisher Scientific)
and Alexa Fluor 555 goat anti-rabbit IgG (1:200; Thermo Fisher Scientific) sec-
ondary Ab for 1 h at room temperature to probe 8-oxo-dG and FASN, respectively.
Immunofluorescence images were taken by TCS SP5 confocal microscope (Leica
Microsystems) at a resolution of 757.6 nm/px.
Extracellular flux analysis. OCR and ECAR were determined by using the XF96
Extracellular Flux Analyzer (Seahorse Bioscience) following the manufacturer’s
protocol. For monolayer culture, MEFs and HC11 cells were seeded at a density of
1 × 104 cells/well (optimal cell-seeding density was optimized in preliminary
experiments) in an XF96-well microplate 12 h before experiments. For spheroid
assays, cells were cultured in ultralow attachment surface plates for at least 3 days.
Spheroids were disaggregated, counted, and plated into the XF96-well microplate.
The microplate was pre-coated with cell adhesive (Cell-tak Cell and tissue adhesive;
Corning) to maintain cells in the proper location. For OCR determination, assays
were initiated by replacing the media with XF assay media supplemented with fresh
sodium pyruvate (1 mM), glutamine (2 mM), glucose (0.5 mg/L), and 10% FBS (pH
7.4), and were equilibrated in non-CO2 incubator at 37 °C for 1 h. Cells were then
placed in the instrument, and oxygen consumption was recorded for almost 90
min. Seahorse Analyzer uses a cartridge with 96 optical fluorescent O2 sensors to
measure OCR (pmol/min). OCR was measured simultaneously in all wells three
times at each step, and a minimum of eight replicates were utilized per condition in
any given experiment. Basal OCR was measured, followed by sequential treatment
of oligomycin A (1 μM), carbonylcyanide-p-trifluoromethoxyphenylhydrazone
(FCCP) (0.9 μM), and rotenone/antimycin (1 μM) (optimal reagent concentrations
were determined in preliminary experiments). For ECAR determination, after 24 h
of incubation, the media was changed to assay medium (XF base medium sup-
plemented with 2 mM glutamine), and cells were incubated in a non-CO2 incu-
bator at 37 °C for 1 h before the assay. Injections of glucose (10 mM), oligomycin
(1 μM), and 2-DG (100 mM) were diluted in the assay medium and loaded into
ports A, B, and C, respectively. The machine was calibrated, and the assay was
performed by using glycolytic stress test assay protocol as suggested by the man-
ufacturer (Seahorse Bioscience). Each treatment was measured every 8 min (4 min
of measurement) three times. All compounds and materials were obtained from
Seahorse Bioscience. Protein concentrations in each well were determined with the
BCA method (Pierce) in cell lysates. Respiration and acidification rates are pre-
sented as mean values ± SEM.
Mitochondrial membrane potential measurements. Cells were loaded with
75 nM of the fluorescent potential-dependent indicator dye (Abcam) for 30 min at
37 °C. The TMRE (tetramethylrhodamine, ethyl ester) dye is a cell-permeant,
positively charged, red-orange dye that readily accumulates in active mitochondria
due to their relative negative charge. The mitochondrial marker Mitotracker green
(Thermo Fisher Scientific) (200 nM) stains mitochondria independently of the
mitochondrial membrane potential. This dye was used as a positive marker of
mitochondria. Uncoupler FCCP (20 μM) was added to FASNlox/lox-PyMT cells as a
negative control. Digital images were taken by a TCS SP5 confocal microscope
(Leica Microsystems) at a resolution of 757.6 nm/px. Images were captured by
using a ×20/0.7NA dry objective, and the optical section was 3.665 μm. Images
were analyzed by using a custom-developed routine programmed on Definiens
Developer v2.5 software (Definiens, Germany); on this routine the identification of
mitochondrial regions was done by using the green channel, and the membrane
potential was quantified by using the regions from these segmented objects on the
red channel. Some samples incubated with 20 µM FCCP, an uncoupler of electron
transport and oxidative phosphorylation, for 10 min prior to staining with TMRE,
served as a positive control for depolarized mitochondria.
ATP citrate lyase activity. MEFs were maintained in ultralow attachment surface
plates for 72 h. ATP-citrate lyase activity was measured by using the mouse ATP-
Citrate Lyase ELISA Kit (LifeSpan BioSciences) following the manufacturer’s
instructions. Optimal cell number was optimized in preliminary experiments.
Briefly, cultured cells (4 × 107) were collected by centrifugation and washed three
times with PBS. Cell pellets were then resuspended in PBS and lysed by ultra-
sonication. Cellular debris was removed by centrifugation. One hundred micro-
liters of supernatant was collected for assaying. After processing, optical density of
each well was determined by using a microplate reader set to 450 nm. Four
replicates were utilized per condition in any given experiment.
Mitochondria isolation and solubilization. Mitochondria were isolated according
to a previously published protocol67. Briefly, cultured cells (4 × 107) were collected
by using trypsin/EDTA solution, and frozen at −80 °C to facilitate cell breakage.
Cell pellets were homogenized by using Potter–Elvehjem glass-teflon homogenizer
backed with electrical support, and adding about ten cell pellet volumes of
homogenizing buffer A (83 mM sucrose, 10 mM MOPS (3-(N-morpholino)pro-
panesulfonic acid)), pH 7.2). An equal volume of buffer B (250 mM sucrose,
30 mM MOPS, pH 7.2) was added, and samples were centrifuged at 1000 × g
during 5 min to remove unbroken cells and nuclei. Mitochondria were collected
from the supernatant by centrifuging at 12,000 × g during 3 min. The pellets were
washed with buffer C (320 mM sucrose, 1 mM EDTA, and 10 mM Tris-HCl, pH
7.4), and centrifugation was repeated at the same conditions. Mitochondrial pellets
were suspended in buffer D (1M 6-amiohexanoic acid, 50 mM Bis-Tris-HCl, pH
7.0), and the membrane proteins were solubilized with digitonin (4 g/g) and
incubated for 5 min in ice. A 30 -min centrifugation at 13,000 × g was performed,
and then the supernatant containing the solubilized mitochondria was collected.
Blue native gel electrophoresis and transfer. The extracted and solubilized
mitochondria were separated by electrophoresis in native gels (NativePAGE Novex
3–12% Bis-Tris Protein Gels, Thermo Scientific) in order to evaluate the
arrangement of the complexes in the electron transport chain. The mitochondrial
samples were loaded in 10% (v/v) loading buffer (5% (v/v) Serva-Blue G; 1M 6-
aminohexanoic acid). The electrophoresis was carried out at 100 V for 1 h in the
presence of blue cathode buffer (50 mM tricine; 15 mM Bis-Tris/HCl; 0.02% (w/v)
Coomassie Brilliant Blue G, pH 7) in the cathode chamber, and anode buffer
(50 mM Bis-Tris, pH 7) in the anode chamber, followed by buffer replacement
(removal of Coomassie blue dye) in the cathode chamber and electrophoresis at
40 V overnight at 4 °C. The gel containing the separated proteins was then incu-
bated at 4 °C in carbonated transfer buffer (10 mM NaHCO3; 3 mM Na2CO3·10
H2O, pH 9.5–10) for 20 min with agitation to ensure that the gel was fully saturated
with said transfer buffer. The transfer was then carried out onto polyvinylidene
difluoride membranes (Thermo Scientific) (previously activated with methanol) at
60 V for 90 min at 4 °C in the Mini-Transblot system (Bio-Rad, USA). The
membranes were then subjected to normal western blot protocol by using anti-
NDUFS1 primary antibody (1:500) (Sc-50132, Santa Cruz) and anti-goat (1:10000)
(ab6741, Abcam) as a secondary antibody.
In-gel activity of complex I. The activity of complex I was evaluated by using in-
gel activity assay. For this, after electrophoresis, gels were washed in running buffer
to eliminate any rest of loading buffer. Then, gels were incubated in fresh activity
solution (0.1 M Tris-HCl, pH 7.4, 1 mg/mL nitro blue tetrazolium chloride, and
0.14 mM NADH) at room temperature during 30–60 min68. Reaction was stopped
by washing the gels with distilled water. Apparition of blue–purple precipitate
indicates the activity of NADH oxidase, one of the activities of complex I, con-
firming by this manner the localization of this complex.
Pyruvate dehydrogenase activity. The PDH activity was determined in isolated
mitochondria from fresh cells (Mitochondria Isolation Kit, BioVision) by using a
coupled enzyme reaction, which results in a colorimetric product proportional to
the enzymatic activity (BioVision). Acetyl-CoA (Sigma) was added directly to the
mitochondrial lysates (10 mM) before the assay.
Cell growth assays. Cell proliferation was measured by counting cells after
trypsinization in 2D cultures. In 3D cultures, spheroids were desegregated before
counting. The average spheroid size was determined by measuring the maximum
cross-sectional area of individual spheroids by using the ImageJ software. A
minimum of ten images per condition were used.
Plasma triglyceride determination. Plasma levels of triglycerides were measured
by using an ABX Pentra Clinical Chemistry benchtop analyzer (Horiba ABX,
Montpellier, France) using the ABX Pentra Triglycerides CP reagent following the
manufacturer’s instructions (Horiba ABX, Montpellier, France). Briefly, blood was
collected by using heparin as the anticoagulant followed by 10 min of centrifuga-
tion at 1500 × g at room temperature. The yellow plasma layer was transferred to
another tube. Three microliters of plasma was used per test, in triplicates.
Oil Red-O staining. Tissues were washed with PBS and then fixed in 10% buffered
formalin for 1 h at room temperature. After washes in PBS, cells were stained for
30 min at room temperature with a filtered Oil Red-O (Sigma) solution (0.5% Oil
Red-O in isopropyl alcohol), washed again in PBS, and visualized under an
inverted microscope (Olympus).
RNA extraction and quantitative RT-PCR. Total RNA was extracted from cells
with TRIzol reagent (Thermo Fisher Scientific) in accordance with the
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manufacturer’s instructions. Briefly, the same quantity of total RNA was retro-
transcribed to complementary DNA (cDNA) by using the Quantitect Reverse
Transcription Kit (Qiagen, Valencia, CA, USA) (2 min at 42 °C, 15 min at 42 °C,
and 3 min at 95 °C). One microliter of the resulting cDNA was placed in a 384-well
plate with 5 μl of Syber Green (Applied Biosystems-Life Technologies, Grand
Island, NY, USA) and 2 µL of the corresponding primers in a final volume of 10 µL.
PCR amplification was performed by using the Applied Biosystems Prism 7900HT
Sequence Detection System (Life Technologies; Grand Island, NY, USA) under the
following thermal cycler conditions: 2 min at 50 °C, 10 min at 95 °C, and 40 cycles
(15 s at 95 °C and 1 min at 60 °C). To quantify transcription, the mRNA expression
levels of the target genes were normalized to β-actin (GGCTCCTAGCACCAT-
GAAGA—forward; CCACCGATCCACACAGAGTA—reverse). The primers used
are as follows: (sequence (5′–3′): FASN-CTGCCACAACTCTGAGGACA (for-
ward) and CGGATCACCTTCTTGAGAGC (reverse); Glut1-GCCCCCAGA
AGGTTATTGA (forward) and CGTGGTGAGTGTGGTGGAT (reverse); Glut4-
ACATACCTGACAGGGCAAGG (forward) and CGCCCTTAGTTGGTCAGAAG
(reverse)).
All samples were run in triplicates, and relative quantification (RQ) was
calculated following the ΔCt method: RQ= 2−ΔCt, where ΔCt is the difference
between the Ct of the gene of interest and the Ct of the endogenous gene control β-
actin. In addition, in knockdown experiments, RQ was normalized as RQ=
2−ΔΔCt, where ΔΔCt is the difference between the ΔCt in knockdown cells and the
ΔCt in control cells.
NAD+ and NADH measurements. Total intracellular NAD+ and NADH were
measured by using the EnzyChrom NAD+/NADH Assay Kit (BioAssay Systems)
following the manufacturer’s instructions.
NADPH assay. Total cell lysates or mitochondrial lysates were used to determine
NADPH levels in 3D culture conditions. Briefly, 20 × 106 cells were cultured in
ultralow attachment surface plates for at least 72 h before NADPH quantification.
Mitochondrial Isolation Kit (BioVision) was used to obtain the mitochondrial
lysates following the manufacturer’s instructions. NADPH levels were assessed in
total cell lysates and mitochondrial lysates by using the NADP/NADPH Assay Kit
(abcam) following the manufacturer’s instructions.
ATP and ADP content. ATP and ADP levels were measured by using the Enzy-
Light ADP/ATP Assay Kit (BioAssay Systems) following the manufacturer’s
instructions.
Apoptosis and ROS measurements. For apoptosis assay, MEFs were stained with
DAPI and Annexin V (cat no. 556547, FITC Annexin V Apoptosis Detection Kit I,
BD Pharmingen™) at room temperature for 5 min and analyzed by flow cytometry
by using a FACSCalibur flow cytometer (FACScalibur, Becton Dickinson). A
representative example of gating strategy used to characterize FASNlox/lox-PyMT
MEFs in apoptosis in 2D cultures, by using co-staining with Annexin-V and DAPI
is shown in Supplementary Fig. 1h. Mitochondria-mediated ROS generation was
detected with the mitochondrial superoxide indicator MitoSOX-Red (Life Tech-
nologies). For 2D measurement of mitochondrial ROS, MEFs, and HC-11, cells
were trypsinized and resuspended in DMEM and RPMI medium with 10% FBS.
After centrifugation, cells were washed twice in PBS and stained with 3 μM of
Coomassie-Red (Life Technologies) for 20 min in PBS for 30 min at 37 °C. Sub-
sequently, the cells were washed twice in PBS, followed by analysis on a FACS
Calibur flow cytometer (Becton Dickinson). For 3D measurement, MEFs and
HC11 cells were cultured in ultralow attachment surface plates for at least 72 h
before ROS quantification. After incubation with MitoSOX-Red, cells were then
washed in PBS with 5 mM EDTA to prevent aggregation of cells for FACS analysis.
DAPI staining was used for cell death detection. Negative controls with no stain
were used in all experiments. The data obtained from flow cytometer were analyzed
by using the FlowJo software (Tree Star, Ashland, OR). Gating strategy to evaluate
ROS content by using MitoSOX-Red is shown in Supplementary Fig. 3e.
Isotope-tracing experiments. For isotope-labeling experiments, glucose or glu-
tamine were replaced with their U-13C-labeled forms (Cambridge Isotope Labs), U-
13C6-glucose, and U-13C5-glutamine, respectively. For all 13C-tracing experiments,
cells were maintained in the labeled medium for 8 h. For 3D culture conditions,
cells were seeded in ultralow attachment surface dishes (Corning).
Metabolite extraction. Metabolites were extracted into the extraction solvent by
adding 220 µL of cold methanol in 0.1% formic acid. Samples were vortexed for 30
s and immersed in liquid N2 to disrupt cell membranes, followed by 30 s of bath
sonication. These two steps were repeated three times. Four hundred and forty
microliters of dichloromethane was added to the resulting suspension, followed by
140 µL of cold water. Cell lysates were vortexed before centrifugation (5000 × g,
15 min at 4 °C), and the polar (aqueous) and nonpolar (lipidic) phase were sepa-
rated and carefully transferred into new tubes. The polar sample was frozen, lyo-
philized, and stored at 80 °C until further mass spectrometry (MS) analysis. The
nonpolar phase was dried under a stream of nitrogen gas before nuclear magnetic
resonance (NMR) analysis.
NMR analysis. Polar (aqueous) samples were analyzed by using positional
enrichment by proton analysis (PEPA). PEPA detects the position of carbon label
in isotopically enriched metabolites and quantifies fractional enrichment by
indirect determination of 13C-satellite peaks by using 1D-H-NMR spectra.
13C NMR spectra of nonpolar (lipidic) samples were recorded at 300 K on an
Avance III 600 spectrometer (Bruker, Germany) operating at a carbon frequency of
150.93 MHz by using a 5-mm CPTCI triple-resonance (1H, 13C, and 31P) gradient
cryoprobe. Power gate-decoupled 13C pulse experiments (“zgpg” in Bruker® pulse
sequence) were carried out by using WALTZ-16 scheme with proton presaturation
and relaxation delay of 10 s. The 90° pulse length was 14.75 ms. The spectral width
was 36 kHz (240 p.p.m.), and a total of 256 transients were collected into 64k data
points for each 13C spectrum. The exponential line broadening applied before
Fourier transformation was 1 Hz. The frequency domain spectra were phased and
baseline-corrected and referenced to the chemical shift of TSP signal at 0 p.p.m. by
using the TopSpin software (version 2.1, Bruker). After preprocessing, specific 13C
NMR peaks around 14.17 p.p.m. characteristic of the terminal CH3 fatty acid were
integrated by using the AMIX 3.9 software package.
Gas chromatography–MS analysis. We incubated the lyophilized polar extracts
with 50 µL of methoxyamine in pyridine (40 µg/µL) for 45 min at 60 °C. To
increase volatility of the compounds, we silylated the samples by using 25 µL of N-
methyl-N-trimethylsilyltrifluoroacetamide with 1% trimethylchlorosilane (Thermo
Fisher Scientific) for 30 min at 60 °C.
A 7890A GC system coupled to a 7200 QTOF or 7000 QqQ MS (Agilent
Technologies, Palo Alto, CA) was used for isotopolog determination. Derivatized
samples were injected (1 µL) in the gas chromatograph system with a split inlet
equipped with a J&W Scientific DB5-MS+DG stationary-phase column
(30 mm × 0.25 mm i.d., 0.1-µm film, Agilent Technologies). Helium was used as a
carrier gas at a flow rate of 1 mL/min in constant flow mode. The injector split ratio
was adjusted to 1:5, and oven temperature was programmed at 70 °C for 1 min and
increased at 10 °C/min to 325 °C. The ionization performed was positive chemical
ionization with isobutene as reagent gas. Mass spectral data on the 7200 QTOF
were acquired in full-scan mode from m/z 35 to 700 with an acquisition rate of
5 spectra per second. Mass spectral data on the 7000 QqQ were acquired in scan
mode monitoring selected ion clusters of the different metabolites.
Liquid chromatography–MS analysis. Polar samples were analyzed by using a
UHPLC system (1290 series, Agilent Technologies) coupled to a 6550 ESI-QTOF
MS (Agilent Technologies) operated in positive (ESI+) and negative (ESI−)
electrospray ionization mode. Metabolites were separated by using C18-RP
(ACQUITY UPLC HSS T3 1.8 μm for ESI+ and BEH 1.7 μm for ESI−, Waters)
chromatography at a flow rate of 0.4 mL/min. The solvent system in C18-RP ESI+
was A= 0.1% formic acid in water, and B= 0.1% formic acid in acetonitrile. The
solvent system C18-RP ESI− was A= 1 mM ammonium fluoride in water (pH ~7)
and B= acetonitrile, as previously reported69. The linear gradient elution started at
100% A (time 0–2 min) and finished at 100% B (10–15 min). The injection volume
was 5 μL by using a flow rate of 0.4 mL/min. ESI conditions: gas temperature,
150 °C; drying gas, 13 L/min; nebulizer, 35 psig; fragmentor, 175 V;skimmer, 65 V.
The instrument was set to acquire over the m/z range 100–1500 in full-scan mode
with an acquisition rate of 4 spectra/s. Tandem MS (MS/MS) was performed in
targeted MS/MS mode, which requires that the masses of selected metabolites be
specified on an inclusion list to ensure that they are subjected to a second stage of
mass selection in an MS/MS analysis. MS/MS experiments were acquired in order
to confirm the identity of unlabeled and labeled peaks detected by the software
geoRge70. We used a default isolation width (the width half-maximum of the
quadrupole mass bandpass used during MS/MS precursor isolation) of 4m/z, and
the collision energy was fixed at 20 eV.
[14C]acetate incorporation into lipid fractions. MEFs were grown in 12-well
plates to 70–80% confluence. MEFs were treated with 1 mCi/mL sodium [1,2-14C]
acetate (PerkinElmer) for 6 h. After two washes with ice-cold PBS, cells were lysed
with 0.6 mL of MeOH solution (MeOH:H2O= 2.5:1). CHCl3 (0.4 mL) was added
to the lysate and mixed by vortexing for 30 s. Lysates were then centrifuged for
5 min at 1000 r.p.m. for phase separation. The lipid-soluble fraction was collected
as the lower layer. Fractions were counted for radioactivity.
Palmitate oxidation. For assessment of palmitate metabolism, FASNlox/lox-PyMT
and FASNΔ/Δ-PyMT MEFs were cultured in monolayer (2D) or spheroid (3D)
culture conditions for 48 h. After that MEFs were washed with PBS 1× twice and
they were incubated in the media containing 20 mM HEPES, 140 mM NaCl,
16.1 mM KCl, 5.1 mM MgSO4, 2.7 mM CaCl2, 1.2 mM L-carnitine, 2% FFA-free
BSA, 0.8 mM palmitate, and 2 μCi [14C]palmitate (PerkinElmer—NEC534050UC)
with pH adjusted to 7.4. For rescue experiments, soraphen A was added to the cells
(200 mM). Following a 4-h incubation period, 1 mL of the medium was transferred
to a 1.5-mL tube, the cap of which housed a Whatman (GF/B) filter paper disc that
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had been presoaked with 200 μL of 1M KOH. [14C]O2 trapped in the media was
then released by acidification of media by using 60% (vol/vol) perchloric acid and
gentle agitation of the tubes at 37 °C for 2 h. Afterward, the filter paper disc was
removed from the cap and placed into 2 mL of scintillation liquid. The remaining
cells were subsequently washed with 2 mL of PBS and lysed in 1 mL of 1 M NaOH
before being transferred into 4 mL of scintillation liquid. Samples were then sub-
jected to liquid scintillation counting (Wallac 1409 Liquid Scintillation counter,
PerkinElmer, Waltham, MA, USA). The protein content of samples was measured
in triplicates by using the Bradford assay.
siRNA knockdown of IDH1. FASN+/+-PyMT MEFs were plated into a 10-cm
dish. After 24 h, the cells were transfected with 50 nM of either siRNA specific for
mouse IDH1 (cat. no. L-045049-00-0005, Dharmacon) or scrambled siRNA (cat.
no. D-001810-01-05, Dharmacon) by using DharmaFECT transfection reagents
(Dharmacon). After 48 or 72 h, the cells were processed for spheroid formation
capacity and OCR assay, and protein was harvested for analysis by immunoblot
(see the “Western blotting” section).
Statistical analysis. Experimental data are presented as the mean ± standard
deviation or mean ± standard error mean. Data were analyzed by Student’s t test to
compare means of two groups by using the GraphPad Prism® Software (La Jolla,
CA). *P < 0.05, **P < 0.01, and ***P < 0.001. Determinations of the significance of
the differences in survival outcomes between FASN+/+; PyMT and FASNΔ/Δ;
PyMT mice were calculated by Kaplan–Meier survival curve comparisons, as well
as the P values derived from log-rank test. Analysis was performed by using the
SPSS software (version 19).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are included in this paper and available
from the corresponding author upon request.
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